Pigs immunized with Chinese highly pathogenic PRRS virus modified live vaccine are protected from challenge with North American PRRSV strain NADC-20  by Galliher-Beckley, Amy et al.
P
l
s
A
A
R
a
b
c
C
d
a
A
R
R
A
A
K
H
J
N
V
P
1
h
$
t
w
P
a
h
T
l
h
0Vaccine 33 (2015) 3518–3525
Contents lists available at ScienceDirect
Vaccine
j o ur na l ho me  page: www.elsev ier .com/ locate /vacc ine
igs  immunized  with  Chinese  highly  pathogenic  PRRS  virus  modiﬁed
ive  vaccine  are  protected  from  challenge  with  North  American  PRRSV
train  NADC-20
my  Galliher-Beckleya,1, Xiangdong  Lia,1,  John  T.  Batesa,  Rachel  Maderaa,
ndrew  Watersa, Jerome  Nietfeldb, Jamie  Henningsonb,  Dongsheng  Hec, Wenhai  Fengd,
uiai  Chenc,  Jishu  Shia,∗
Department of Anatomy and Physiology, Kansas State University, Manhattan, KS, USA
Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA
State Key Laboratory of Biotechnology and Bio-products Development for Animal Epidemic Prevention, South China Agricultural University, Guangzhou,
hina
State Key Laboratory of Agro-biotechnology, China Agriculture University, Beijing, China
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 13 January 2015
eceived in revised form 13 May  2015
ccepted 22 May  2015
vailable online 3 June 2015
eywords:
ighly pathogenic PRRS virus
XA-1
ADC-20
a  b  s  t  r  a  c  t
Modiﬁed  live  virus  (MLV)  vaccines  developed  to protect  against  PRRSV  circulating  in North  America  (NA)
offer  limited  protection  to highly  pathogenic  (HP)  PRRSV  strains  that  are  emerging  in Asia.  MLV  vaccines
speciﬁc  to  HP-PRRSV  strains  commercially  available  in China  provide  protection  to  HP-PRRSV;  however,
the  efﬁcacy  of these  HP-PRRSV  vaccines  to  current  circulating  NA  PRRS  viruses  has  not been  reported.  The
aim of this  study  is  to  investigate  whether  pigs  vaccinated  with  attenuated  Chinese  HP-PRRSV  vaccine
(JXA1-R)  are  protected  from  infection  by  NA  PRRSV  strain  NADC-20.  We  found  that  pigs  vaccinated  with
JXA1-R  were  protected  from  challenges  with HV-PRRSV  or NADC-20  as  shown  by  fewer  days  of clinical
fever,  reduced  lung  pathology  scores,  and  lower  PRRS  virus  load  in the  blood.  PRRSV-speciﬁc  antibodies,
as measured  by  IDEXX  ELISA,  appeared  one  week  after  vaccination  and  virus  neutralizing  antibodiesaccine
ig
were  detected  four  weeks  post  vaccination.  Pigs  vaccinated  with  JXA1-R  developed  broadly  neutralizing
antibodies  with  high  titers  to  NADC-20,  JXA1-R,  and  HV-PRRSV.  In  addition,  we  also  found  that  IFN-  and
IFN-  occurred  at higher  levels  in the  lungs  of  pigs  vaccinated  with  JXA1-R.  Taken  together,  our  studies
provide  the  ﬁrst  evidence  that JXA1-R  can confer  protection  in  pigs  against  the  heterologous  NA  PRRSV
strain  NADC-20.
ublis© 2015  The  Authors.  P
. Introduction
Porcine reproductive and respiratory syndrome (PRRS) is a
ighly devastating swine viral disease, which causes more than
664 million in losses within the U.S. annually [1]. PRRS is caused by
he porcine reproductive and respiratory syndrome virus (PRRSV),
hich is a member of the genus Arterivirus,  family Arteriviridae.
RRSV infection leads to respiratory distress in pigs of all ages
nd reproductive failure in sows, and pigs infected with PRRSV
ave enhanced susceptibility to secondary microbial infections [2].
he North American prototypic strain of PRRSV, VR-2332, was  iso-
ated in 1987 [2]. Pigs infected with VR-2332 in an experimental
∗ Corresponding author. Tel.: +1 785 532 4506.
E-mail address: jshi@ksu.edu (J. Shi).
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article uhed  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
setting display few clinical symptoms and only slight changes in
lung pathology [3]. Modiﬁed live virus (MLV) vaccines based off VR-
2332 (Ingelvac PRRS MLV) have been shown to provide complete
protection from infection by VR-2332 [4]. However, these vaccines
are only able to partially protect pigs from newly emerging het-
erologous PRRSV strains [5,6]. In 2001, the NADC-20 strain was ﬁrst
isolated in an “atypical PRRSV abortion storm” and, compared with
earlier isolates, NADC-20 is more virulent as it can cause dyspnea,
mild lethargy, and moderate proliferative interstitial pneumonia
in infected pigs [7]. Today, NADC-20 remains one of the most vir-
ulent strains of PRRSV circulating in North America, which makes
it a suitable challenge strain for PRRSV vaccine efﬁcacy evaluation
[8,9].In 2006, highly pathogenic PRRSV (HP-PRRSV) strains ﬁrst
emerged in China, and infected pigs developed clinical signs includ-
ing high fever (≥41 ◦C), anorexia, listlessness, red discoloration of
skin, respiratory distress with very high morbidity and mortality
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ates [10]. Thus far, HP-PRRSV strains have been detected in
ost countries in East Asia including Cambodia, Laos, Philippines,
hutan, Myanmar, Thailand, South Korea, and Russia [11]. JXA-1
GenBank ID: EF112445.1), one of the earliest HP-PRRSV strains,
as isolated in 2006 and shares 91% homology with the genome of
R-2332 (GenBank ID: AY150564.1). However, during the preva-
ence of HP-PRRSV from 2006 to 2009, commercial PRRSV vaccines
ased off the VR-2332 strain failed to protect pigs from HP-
RRSV infection. This challenge led to the development of the ﬁrst
P-PRRS MLV  (JXA1-R) from the JXA-1 isolate in China [12–14].
ubsequently, two additional commercial HP-PRRS MLV vaccines,
JM-F92 and HuN4-F112, were also introduced into the Chinese
wine industry, all providing adequate protection of pigs to HP-
RRSV infection [15,16].
Although HP-PRRSV has not been detected in swine farms in the
.S., the possibility of an outbreak of this high virulent PRRSV in
orth America cannot be dismissed. This danger has become more
elevant in light of recent epidemic of Porcine Epidemic Diarrhea
irus (PEDV) in North America [17–19], another high consequence
wine virus that was widespread in Asia. Therefore, it is important
o determine whether current commercial vaccines for HP-PRRSV
i.e. JXA1-R) are safe and effective against HP-PRRSV in a U.S. setting
n order to prepare U.S. swine farms from a potential attack of HP-
RRSV.
Furthermore, compared with VR-2332, HP-PRRSV can elicit
tronger immune responses as evidenced by a striking induction
f cytokines associated with both innate and adaptive immunity
n pigs infected with HP-PRRSV [16]. Therefore, it is possible that
P-PRRS MLV  vaccines may  also elicit a stronger immune response
n pigs that can result in broader protection against heterologous
RRSV strains circulating in the U.S. To test our hypothesis, pigs
accinated with JXA1-R were challenged with HV-PRRSV (a highly
athogenic strain of PRRSV from China) or NADC-20. Here we pro-
ide the ﬁrst evidence that JXA1-R not only is safe and efﬁcacious
gainst HP-PRRSV in an experimental setting in the U.S., but also
an protect pigs against virulent NA PRRSV strain NADC-20. This
rotection likely results from the induction of high levels of NADC-
0-speciﬁc neutralizing antibodies and pulmonary IFN- and IFN-
n pigs vaccinated with JXA1-R.
. Materials and methods
.1. Cells and virus
MARC-145 cells were maintained in modiﬁed Eagle’s medium
MEM)  as described previously [20]. HV-PRRSV is a Chinese HP-
RRS virus isolated from the lymph node of an infected pig and
equenced in 2012 (GenBank accession no. JX317649) [21]. Con-
truction of the plasmid encoding the infectious clone cDNA has
een previously described [22]. This plasmid was transfected using
ipofectamine (Life Technologies) into MARC-145 cells. CPE was
vident several days after transfection, and the virus was expanded
or two more passages in MARC-145 cells. Virus harvested after pas-
age three was used in the study. NADC-20 PRRSV was a kind gift
rom Dr. Kelly Lager (National Animal Disease Center, USDA-ARS,
mes, IA). JXA1-R (a HP-PRRS MLV  vaccine) was a kind gift from
uangdong Dahuanong Animal Health Product Co., Ltd. VR-2332
nd MN184A strains were described previously [3].
.2. Pigs, vaccination and challengeThirty ﬁve conventional Large White–Duroc crossbred weaned
peciﬁc-pathogen free piglets (3 weeks of age) were used for this
tudy. The study protocol was approved by the Institutional Ani-
al  Care and Use Committee at Kansas State University. All pigletsne 33 (2015) 3518–3525 3519
were conﬁrmed sera-negative for antibodies to PRRSV by ELISA and
PRRSV-free in the blood by RT-PCR. Pigs were allowed to acclimate
for one week before initiation of the experiments. The 35 pigs were
divided into seven groups (5 pigs/group) with three groups (15
pigs) housed within BSL-3Ag conditions at the Biosecurity Research
Institute (BRI) and the other four groups (20 pigs) housed within
BSL-2 conditions at the Large Animal Research Center (LARC) facil-
ity, Kansas State University.
For the 15 pigs housed in the BSL-3Ag facility, on day 0, ﬁve
pigs in one group were immunized intramuscularly with a single
dose of JXA1-R, and the other two groups of pigs were mock vac-
cinated with PBS as controls. Vaccinated pigs and controls were
housed in different rooms. On day 28 post vaccination, 10 pigs (ﬁve
pigs from the vaccinated group, ﬁve pigs from the control group)
were challenged with HV-PRRSV (2 × 105 TCID50/pig), and these
two groups of pigs were housed in separate pens in the same room.
The other ﬁve control pigs were mock challenged with PBS and
housed in a separate room. Half of the challenge virus or mock
control was administered intramuscularly and half was admin-
istered intranasally. Pigs were monitored for rectal temperature
for the ﬁrst eight days after challenge. Pigs with rectal tempera-
tures above 40 ◦C were considered to have fever [23]. Body weights
were recorded and blood samples were collected every seven days
after vaccination and every three days after viral challenge. All pigs
that survived challenge were humanely euthanized at 10 days post
challenge (DPC).
For the 20 pigs housed in the BSL-2 facility, on day 0, two groups
of pigs (10) were immunized intramuscularly with a single dose
of JXA1-1R vaccine. The other two  groups of pigs were mock vac-
cinated with PBS as controls. Vaccinated pigs and controls were
housed in different rooms. On day 28 post vaccination, 10 pigs (one
group of vaccinated and one group of control pigs) were commin-
gled and then challenged with NADC-20 (2 × 105 TCID50/pig), the
other 10 pigs were commingled and mock challenged with PBS and
housed in a separate room. Half of the challenge virus or mock
control was  administered intramuscularly and half was  adminis-
tered intranasally. Pigs were monitored for rectal temperature for
the ﬁrst eight days after challenge. Body weight and blood samples
were collected every seven days after vaccination and every three
days after viral challenge. All pigs were humanely euthanized at
10 DPC.
Gross lung lesions were evaluated independently by two pathol-
ogists. Blood and lung samples were further processed for lung
pathology, viral load, cytokine expression, PRRSV-speciﬁc antibod-
ies, and PRRSV neutralizing antibody titer, as described below. Sera
collected during a previous study [3] and stored at −80 ◦C were
used to determine if pigs immunized with Ingelvac PRRSV MLV
developed HP-PRRSV-neutralizing antibodies.
2.3. Serum isolation, ELISAs, virus quantitation
Serum was separated from clotted blood and preserved at
−20 ◦C. Serum samples were used for evaluation of viral titer and
PRRSV-speciﬁc antibody titers using IDEXX HerdChek ELISA kits
as described previously [3]. Pig serum samples at 6 DPC and the
supernatants of lung homogenates were used to analyze cytokine
expression. Lung homogenates were prepared as described pre-
viously [16]. IFN- and IFN- ELISA kits were purchased from
Abcam (Abcam, Cambridge, MA). The TNF- ELISA kit was  pur-
chased from Invitrogen (Life Technologies, Carlsbad, CA). All ELISA
procedures were performed as per the manufacturer’s instructions.
The One-step Taq-Man qPCR was  performed to calculate PRRSV
RNA copy number in the serum sample according to manufacturer’s
instructions (EZ-PRRSVTM MPX4.0 Real Time RT-PCR, Tetracore Inc.,
Rockville, MD)  as we described earlier [5].
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.4. Virus neutralizing titer in serum
Serum samples were heat inactivated (56 ◦C, 30 min) and seri-
lly diluted before the titration. The serial dilutions of serum were
ixed with equal volume of PRRSV strains: VR-2332, MN184A,
ADC-20, JXA1-R, and HV-PRRSV containing 200 TCID50 of virus.
fter incubation at 37 ◦C for 1 h, the mixtures were transferred to
ARC-145 monolayers in 96-well plates and incubated for an addi-
ional 72 h at 37 ◦C in a humidiﬁed atmosphere containing 5% CO2.
ells were then examined for cytopathic effects (CPE). End-point
iters were calculated as the reciprocal of the ﬁrst serum dilution
o eliminate 90% of the CPE resulting from the inoculation of 200
CID50 into wells of a 96-well plate. A neutralizing titer of 20 indi-
ates that a 1 to 20 dilution of serum eliminated 90% of CPE in the
ells relative to control wells. Each sample was assayed in dupli-
ate. Animals with a titer of greater than eight are considered to be
rotected from viremia [24].
.5. Lung pathology analysis
At necropsy, the lungs were macroscopically evaluated as pre-
iously described [25]. Brieﬂy, the dorsal and ventral surfaces of
ach lung lobe were given a score representing the approximate
roportion that was consolidated. Individual lobe scores were used
o determine an overall lung score representing the percentage of
he total lung that was macroscopically pneumonic. Postmortem
ndings and scoring of macroscopic lung pathology were done in a
linded fashion by two veterinary pathologists at the Kansas State
eterinary Diagnostic Laboratory.
.6. Statistical analysis
All data were expressed as the mean ± SEM (5 or 10 pigs/group).
he differences in the level of body temperature, lung pathology
core, humoral response, cytokine production, and viremia among
ach group were determined by the one-way analysis of variance
ANOVA) followed by post-hoc Tukey’s test using Sigmaplot 11
oftware (Systat Software Inc., San Jose, CA). Differences were con-
idered statistically signiﬁcant when p < 0.05.
. Results
.1. Pigs vaccinated with JXA1-R were protected from challenges
ith HV-PRRSV or NADC-20
Although JXA1-R is a commercial vaccine that has been widely
sed in China, its efﬁcacy in the U.S. has not been reported before
his study. Consistent with our previous report [26], HV-PRRSV
aused signiﬁcant mortality in young pigs (Fig. 1A). Under the BSL-
Ag setting in the current study, three of ﬁve unvaccinated pigs
ied within 6 DPC with HV-PRRSV. Compared to control and pigs
accinated with JXA1-R, unvaccinated pigs had more days with high
ever (>40.5 ◦C, Fig. 1B), lost signiﬁcant body weight (Fig. 1C), and
xhibited higher levels of viremia (Fig. 1D) after HV-PRRSV chal-
enge. These results demonstrated that pigs vaccinated with JXA1-R
ere protected from HV-PRRSV challenge.
NADC-20 has been used for viral challenge to evaluate the
fﬁcacy of potential PRRSV vaccines in the U.S. [8]. We  vac-
inated pigs with JXA1-R on day 0 and challenged them with
ADC-20 28 days post vaccination (DPV). In contrast to pigs
hallenged with HV-PRRSV, all pigs challenged with NADC-20
urvived (Fig. 1E). We  found that unvaccinated pigs challenged
ith NADC-20 developed clinical fever (≥400C) at 1, 5, 7, and
 DPC (Fig. 1F), which is consistent with a previous study [8].
nvaccinated pigs also had slightly reduced weight gain follow-
ng challenge relative to vaccinated animals (Fig. 1G). Consistentne 33 (2015) 3518–3525
with previous studies [20], vaccine virus circulating in the blood
peaked at 14 DPV and returned to undetectable levels by 28 DPV
(Fig. 1H). After HV-PRRSV and NADC-20 challenge, the circulat-
ing viral loads in all groups of pigs were at similar levels three
days after challenge. However, by 7 DPC, the level of circulating
HV-PRRSV (Fig. 1D) and NADC-20 virus (Fig. 1H) in surviving unvac-
cinated pigs was  signiﬁcantly higher than in pigs that had been
immunized.
The body weight gain of pigs was monitored throughout the
study. Interestingly, pigs vaccinated with JXA1-R had signiﬁcantly
(p < 0.05) lower body weight gain than that of unvaccinated pigs
at three and four weeks post vaccination when they were housed
at the BSL-2 facility (Fig. 1G). However, after NADC-20 challenge,
the unvaccinated pigs challenged with NADC-20 showed minimal
growth, while vaccinated pigs had signiﬁcantly higher body weight
gain during the challenge period. Thus, by the end of this study, no
signiﬁcant differences in body weight gain were observed among
the three groups: pigs vaccinated with JXA1-R with or without
NADC-20 challenge and unvaccinated pigs challenged with NADC-
20. Notably, a signiﬁcant difference in body weight existed between
unvaccinated pigs and the pigs exposed to JXA1-R and/or NADC-20
at the end of this study (Fig. 1G). However, this vaccination-related
impact on growth was  not seen when pigs were housed at the
BSL-3Ag facility (Fig. 1C).
3.2. Pigs vaccinated with JXA1-R had reduced lung pathology
following PRRSV challenge
Pigs infected with HV-PRRSV showed more severe and exten-
sive pneumonia than NADC-20 infected pigs, and the mean gross
lung lesion scores for pigs challenged with HP-PRRSV and NADC-
20 were 51% and 25.6%, respectively (Fig. 2). Lung damage in pigs
vaccinated with JAX-1R and then challenged with HV-PRRSV or
NADC-20 was  signiﬁcantly less than that in control pigs following
PRRSV challenge (Fig. 2).
3.3. Pigs vaccinated with JXA1-R developed higher titers of
PRRSV-speciﬁc IDEXX ELISA antibodies and NADC-20
strain-speciﬁc neutralizing antibodies
To monitor the humoral immune responses in pigs exposed to
PRRS virus, we measured serum PRRSV-speciﬁc antibody levels
before and after vaccination and challenge. As shown in Fig. 3A, low
levels of PRRSV-speciﬁc antibodies can be detected at 7 DPV only in
pigs vaccinated with JXA1-R, with all vaccinated pigs seroconvert-
ing by 14 DPV. After NADC-20 challenge, all serum samples from
unvaccinated-NADC-20 challenged pigs became PRRSV-positive
with an average s/p value of 0.5 at 6 DPC (34 DPV). Unvaccinated
pigs that were co-mingled with pigs that received the live vaccine
but were never challenged had PRRSV-speciﬁc serum antibodies
eight days after co-mingling (Fig. 3A).
To determine whether JXA1-R can induce a broad spectrum
of PRRSV neutralizing antibodies, the titers of PRRSV neutraliz-
ing antibodies directed against NADC-20, JXA1-R (vaccine strain),
and HV-PRRSV (a HP-PRRSV strain similar to JXA-1) were deter-
mined at 28 DPV and 10 DPC (Fig. 3B–D). Twenty-eight DPV,
neutralizing antibodies to the three strains of PRRSV tested
were not detected in serum from unvaccinated pigs. In contrast,
serum from pigs vaccinated with JXA1-R contained measurable
titers of NADC-20-neutralizing activity (>4, Fig. 3B), JXA1-R (>12,
Fig. 3C), and HV-PRRSV (>8, Fig. 3D). Furthermore, neutraliz-
ing antibody titers to NADC-20 increased in vaccinated pigs
following challenge and resulted in titers above 12 by 37 DPV
(Fig. 3B).
A. Galliher-Beckley et al. / Vaccine 33 (2015) 3518–3525 3521
Fig. 1. Pigs vaccinated with JXA1-R were protected from challenge with HV-PRRSV and NADC-20. Pigs were immunized with JXA1-R on day 0 and challenged with HP-PRRSV
strain  HV PRRSV or North American strain NADC-20 on day 28. Shown are survival rates of pigs after challenge with HV-PRRSV (A) or NADC-20 (E). Rectal temperature of all
pigs  was monitored daily after PRRSV infection with HV-PRRSV (B) or NADC-20 (F). Fold of total body weight gain during the study was calculated by considering the weight
of  the pig on day 0 as 1 (C and G). The copies of PRRSV RNA in serum samples were determined by qPCR (D and H). Data are shown as mean ± SEM for ﬁve pigs per group. *
p  < 0.05.
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Fig. 2. Pigs vaccinated with JXA1-R are protected from lung pathology induced by
NADC-20 challenge. On day 38 (10 DPC) of the study, all surviving pigs were eutha-
nized and a necropsy was  performed. The gross lung lesions present in all lobes of
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the lung was  evaluated using a 100 point scale. Data are shown as mean ± SEM for
ve  pigs per group with the exception of unvaccinated and unchallenged group in
hich n = 10. * p < 0.05.
.4. Pigs vaccinated with Ingelvac PRRS MLV  failed to develop
road PRRS virus neutralizing antibodies
To determine whether vaccination with Ingelvac PRRS MLV  can
nduce broadly neutralizing antibodies in pigs, the titers of neutral-
zing antibodies against VR-2332 (the parental strain of Ingelvac
RRS MLV  vaccine), MN184A (a virulent North American PRRSV
train), and HV-PRRSV (a HP-PRRSV strain) were measured using
era collected from an earlier study [3]. Brieﬂy, pigs were immu-
ized on day 0 with the Ingelvac PRRS MLV  and challenged with
R-2332 or MN184A on day 28 post vaccination. Sera collected
n days 28 and 35 post vaccination were assayed for PRRS virus
eutralizing antibody titers against VR-2332, MN184A, and HV-
RRSV. As shown in Fig. 3E, by 28 DPV, pigs vaccinated with the
ngelvac PRRS MLV  developed titers of virus neutralizing antibod-
es to VR-2332 (parental vaccine strain). By 35 DPV, neutralizing
ntibody titers to MN184A were only present at protective titers
>8) in vaccinated pigs challenged with MN184A virus. The titers of
P-PRRSV-speciﬁc neutralizing antibodies in pigs vaccinated with
ngelvac PRRS MLV  never reached protective levels (Fig. 3E). These
esults show that unlike JXA1-R, vaccination with Ingelvac PRRS
LV  does not induce broadly neutralizing antibodies in pigs.
.5. JXA1-R vaccination increases IFN-  ˛ and IFN-ˇ, but decreases
NF-  ˛ production in pigs
To determine whether cytokines may  play an important role in
XA1-R-mediated protection against NADC-20, we measured the
evels of IFN-, IFN-, and TNF- in serum samples collected at
 DPC and supernatants of lung homogenates collected at necropsy
10 DPC). The levels of IFN- and IFN- were signiﬁcantly higher in
he lung homogenates from pigs vaccinated with JXA1-R than those
rom control pigs before and after NADC-20 challenge (Fig. 4A and
).
The levels of TNF- in sera and lung homogenates increased in
nvaccinated pigs after NADC-20 challenge but not in pigs vacci-
ated with JXA1-R (Fig. 4C). No signiﬁcant changes in IL-4, IL-8,
L-10 and IFN- levels were detected (data not shown).. Discussion
Traditional PRRS vaccines (MLV or killed) are only able to par-
ially protect pigs from newly emerging heterologous HP-PRRSVne 33 (2015) 3518–3525
strains in Asia [27,28]. Here we present data showing vaccina-
tion with JXA1-R protects pigs from challenge with homologous
HP-PRRSV and reduces viremia and lung pathology in pigs chal-
lenged with NADC-20, a heterologous a North American native
PRRSV strain that often is used for vaccine efﬁcacy evaluation in
the U.S. [8,9]. JXA1-R has been shown previously to stimulate effec-
tive immunity against its parental virus [29]. Our report is the ﬁrst
to show that JXA1-R is safe and effective at stimulating immunity
against commercially relevant North American PRRS viruses in an
experimental setting in the U.S.
Although current attenuated PRRS vaccines in the U.S. are effec-
tive against NADC-20, they can only provide partial protection
against HP-PRRSV [30]. This phenomenon is consistent with the
notion that PRRS vaccines are less effective in inducing cross-
protection against viral isolates that are signiﬁcantly different from
the vaccine strains. Thus, we  were surprised that JXA-1R, a HP-
PRRSV-derived vaccine can provide effective protection against
NADC-20, a non-HP-PRRSV strain that is genetically heterologous
to JXA-1, the parental strain of JXA-1R.
The ability of JXA1-R to stimulate effective immunity against the
heterologous NADC-20 likely results from two  aspects of the virus’s
biology. JXA1-R differs at 47 amino acids relative to its parental
virus, and over half of these difference occur in the non-structural
proteins (nsp) [29]. Though the exact role of all these mutations
in the pathogenesis of the virus has not yet been determined,
the role of the nsp in suppressing the innate immune response is
well-established [31–33]. Mutations in genes coding for nsp likely
account for our observation of increased IFN- and IFN- levels
in the lungs of pigs immunized with JXA1-R (Fig. 4). The reduced
ability of JXA1-R to disrupt the innate immune response ultimately
results in a more effective adaptive response.
A signiﬁcant portion of this adaptive response is directed against
GP5. The GP5 proteins of JXA1-R (GenBank ABL60902.1) and NADC-
20 (GenBank AFW98878.1) are both 200 amino acids long share
90.5% identity. Most of the differences between the two  proteins
occur towards the amino terminus of the protein, with 13 of the 19
differences occurring in the ﬁrst 60 amino acids. These 60 amino
acids constitute a large portion of the ectodomain of GP5 which
comprises neutralizing epitopes [34–36], a decoy epitope [37], and
multiple glycosylation sites [38–40]. Five variable sites that corre-
spond to cross neutralization have been identiﬁed in GP5 of North
American ﬁeld isolates, and three of these sites (aa 32–34, 38–39,
and 57–59) lie within the ﬁrst 60 aa of GP5 [41]. JXA1-R and NADC-
20 have aa sequence differences at each of the sites located in the
ﬁrst 60 aa, but the remaining two sites are conserved between
the two viruses. Thus the ability of JXA1-R to stimulate heterol-
ogous immunity may  result from the elicitation of antibodies that
recognize these previously deﬁned and conserved targets.
However, this proposed mechanism underlying the heterol-
ogous immunity elicited by JXA1-R does not explain why live
vaccines based on North American strains of PRRSV, such as
Ingelvac PRRS MLV, are unable to stimulate protective levels of
neutralizing antibodies speciﬁc for HP-PRRSV strains (Fig. 3E) or
signiﬁcantly reduce lung pathology scores following challenge with
HP-PRRSV [27]. Three of the 13 amino acid differences in the N-
term of GP5 result in asparagine (N) residues in JXA1-R that are not
present in NADC-20 (for a net increase of two N residues). These
residues may  create glycosylation sites that prevent this portion
of JXA1-R GP5 from being a dominant target in the GP5-specﬁc
antibody response. Others have previously shown N-linked gly-
cosylation in this region of GP5 to have a signiﬁcant impact on
the neutralizing antibody response [39,40] and that immunization
with inactivated PRRSV bearing hypo-glycosylated GP5 results in
enhanced immunity [42]. If the dominant neutralizing epitopes in
the JXA1-R GP5 are glycan shielded, the shielding may focus the
immune response toward the conserved epitopes elsewhere on the
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Fig. 3. Pigs vaccinated with JXA1-R developed higher titers of PRRSV-speciﬁc IDEXX ELISA antibodies and NADC-20 strain-speciﬁc neutralizing antibodies. (A) PRRSV-speciﬁc
antibodies in serum samples were measured with IDEXX HerdChek ELISA kits. The threshold for seroconversion was set at a sample-to-positive (s/p) ratio of 0.4 according to
manufacturers’ instructions. (B–D) Serum from each pig was  titered in duplicate in MARC-145 cells for the levels of PRRSV neutralizing antibodies on 28 days post vaccination
(28  DPV) or 9 DPC (37 DPV). End-point titers were calculated as the reciprocal of the ﬁrst serum dilution to eliminate 90% of the CPE resulting from the inoculation of 200
TCID50  into wells of a 96-well plate. Each sample was assayed in duplicate. Animals with a titer of greater than eight are considered to be protected from viremia. (E) Pigs
were  vaccinated with Ingelvac PRRS MLV  on day 0 and challenged with North American PRRSV strains VR-2332 or MN184A on day 28. The levels of PRRSV neutralizing
antibodies on 28 days post vaccination [MLV (D28)] or 7 DPC [MLV + VR-2332/MN184A (D35)] were determined as above. Data are shown as mean ± SEM for ﬁve pigs per
group.  * p < 0.05.
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irus. Trujillo and colleagues have reported that glycosylation of
mmunodominant epitopes in caprine arthritis encephalitis virus
an enhance vaccine-induced, cross-reactive neutralizing antibody
esponses [43]. In that study, the immunodominant epitope was
ot a neutralizing epitope and glycosylation redirected the immune
esponse to a neutralizing epitope. For PRRSV, additional glycosy-
ation in the immunodominant region of JXA1-R GP5, may  redirect
he immune response to subdominant, neutralizing epitopes that
re shared with NADC-20 GP5. This scenario is a plausible expla-
ation for the ability of JXA1-R to elicit NADC-20-neutralizing
ntibodies without North American strains eliciting a protective
esponse against strains of HP-PRRSV circulating in China. Addi-
ional studies are required to conﬁrm or disprove this hypothesis.
. Conclusion
Our study provides the ﬁrst evidence that JXA1-R can confer pro-
ection in pigs against NA PRRSV strain NADC-20. The availability of
 safe and effective HP-PRRS vaccine such as JXA1-R in North Amer-
ca may  not only increase the preparedness for a possible epidemic
f HP-PRRSV in this region, but also offer extra tools to protect pigs
gainst virulent PRRSV strains native to North America.
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